UCB and Amgen have announced top-line results from the STRUCTURE trial (STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopausal women with osteoporosis at high risk for… …read more
UCB and Amgen have announced top-line results from the STRUCTURE trial (STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopausal women with osteoporosis at high risk for… …read more